Back to top

Orexigen Therapeutics (OREX) in Focus: Stock Tumbles 14.7%
June 12, 2014

Read MoreHide Full Article

Orexigen Therapeutics, Inc. (OREX - Free Report) saw a big move in the last trading session, as the company’s shares fell by nearly 15% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent uptrend for OREX, as the stock is up nearly 7% in the past one-month time frame.

The biopharmaceutical company has not seen any estimate revision over the past month, and the current year earnings consensus hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, especially on earnings estimates following the recent slump.

OREX currently holds a Zacks Rank #4 (Sell) while its Earnings ESP is positive.

Investors interested in the Drugs industry may consider better-ranked stocks like ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Gilead Sciences Inc. (GILD - Free Report) and Osiris Therapeutics, Inc. , each of which holds a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Orexigen Therapeutics, Inc. (OREX) - free report >>

ANI Pharmaceuticals, Inc. (ANIP) - free report >>

Gilead Sciences, Inc. (GILD) - free report >>

More from Zacks Tale of the Tape

You May Like